Bin Xu1, Rene Serrette1, R Michael Tuttle2, Bayan Alzumaili1, Ian Ganly3, Nora Katabi1, Giovanni Tallini4, Ronald Ghossein1. 1. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York. 2. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. 4. Department of Experimental, Diagnostic and Specialty Medicine-Anatomic Pathology, University of Bologna School of Medicine, Bologna, Italy.
Abstract
Background: The percentage of papillae is a crucial criterion in differentiating noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) from papillary thyroid carcinomas (PTCs) and in subclassifying PTC into classic and follicular variant. Since the description of NIFTP, three studies have shown that the presence of any papillae may be associated with nodal metastasis, which led to modification of the NIFTP criterion from <1% papillae to no true papillae allowed. We aim at providing clinical evidence-based data on the impact that papillary growth has on nodal spread and tumor genotype in tumors previously diagnosed as encapsulated unifocal PTC. Methods: A meticulous histopathologic examination was performed on 235 cases previously diagnosed as unifocal encapsulated PTC (U-EPTC). One hundred of these cases were subjected to BRAFV600E and NRASQ61R immunohistochemistry. Results: In our cohort, 27 patients (12%) had lymph node metastasis (N1) at the time of initial resection. Overall, 89% of the tumors in the N1 group contained ≥50% papillae, compared with 13% in the N0/Nx group. Nodal metastases were only present in tumors with ≥1% papillae. In noninvasive U-EPTC (n = 161), N1 disease was seen only in tumors with ≥10% papillae. A higher percentage of papillae within the tumor also correlated with an increased frequency of BRAFV600E and decreased rate of NRASQ61R. None of the 26 NRAS-positive cases had nodal disease, including the invasive tumors. Among 216 patients with follow-up (median: 5.2 years), 3 patients (1.5%) had distant metastases, all detected at the initial presentation. All three tumors displayed 100% follicular growth, and capsular or vascular invasion. There was no locoregional recurrence in the entire cohort. Conclusion: In U-EPTC, there is a strong correlation between high percentage of papillary growth, presence of nodal metastasis, and BRAF+/RAS- genotype regardless of invasive status. Nodal metastases were not seen in tumors with <1% papillae irrespective of invasive status. These findings indicate that the initial criterion of <1% papillae is still valid for the diagnosis of NIFTP. Reinstituting this criterion will spare a carcinoma diagnosis and unnecessary therapy with its side effects on patients who have negligible clinical risk.
Background: The percentage of papillae is a crucial criterion in differentiating noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) from papillary thyroid carcinomas (PTCs) and in subclassifying PTC into classic and follicular variant. Since the description of NIFTP, three studies have shown that the presence of any papillae may be associated with nodal metastasis, which led to modification of the NIFTP criterion from <1% papillae to no true papillae allowed. We aim at providing clinical evidence-based data on the impact that papillary growth has on nodal spread and tumor genotype in tumors previously diagnosed as encapsulated unifocal PTC. Methods: A meticulous histopathologic examination was performed on 235 cases previously diagnosed as unifocal encapsulated PTC (U-EPTC). One hundred of these cases were subjected to BRAFV600E and NRASQ61R immunohistochemistry. Results: In our cohort, 27 patients (12%) had lymph node metastasis (N1) at the time of initial resection. Overall, 89% of the tumors in the N1 group contained ≥50% papillae, compared with 13% in the N0/Nx group. Nodal metastases were only present in tumors with ≥1% papillae. In noninvasive U-EPTC (n = 161), N1 disease was seen only in tumors with ≥10% papillae. A higher percentage of papillae within the tumor also correlated with an increased frequency of BRAFV600E and decreased rate of NRASQ61R. None of the 26 NRAS-positive cases had nodal disease, including the invasive tumors. Among 216 patients with follow-up (median: 5.2 years), 3 patients (1.5%) had distant metastases, all detected at the initial presentation. All three tumors displayed 100% follicular growth, and capsular or vascular invasion. There was no locoregional recurrence in the entire cohort. Conclusion: In U-EPTC, there is a strong correlation between high percentage of papillary growth, presence of nodal metastasis, and BRAF+/RAS- genotype regardless of invasive status. Nodal metastases were not seen in tumors with <1% papillae irrespective of invasive status. These findings indicate that the initial criterion of <1% papillae is still valid for the diagnosis of NIFTP. Reinstituting this criterion will spare a carcinoma diagnosis and unnecessary therapy with its side effects on patients who have negligible clinical risk.
Authors: Anna Felisiak-Goląbek; Shingo Inaguma; Artur Kowalik; Bartosz Wasąg; Zeng-Feng Wang; Sebastian Zięba; Liliana Pięciak; Janusz Ryś; Janusz Kopczynski; Maarit Sarlomo-Rikala; Stanislaw Góźdź; Jerzy Lasota; Markku Miettinen Journal: Appl Immunohistochem Mol Morphol Date: 2018-01
Authors: Ricardo V Lloyd; Sylvia L Asa; Virginia A LiVolsi; Peter M Sadow; Arthur S Tischler; Ronald A Ghossein; R Michael Tuttle; Yuri E Nikiforov Journal: Hum Pathol Date: 2018-01-16 Impact factor: 3.466
Authors: Brooke E Howitt; Sue Chang; Markus Eszlinger; Ralf Paschke; Michael G Drage; Jeffrey F Krane; Justine A Barletta Journal: Am J Clin Pathol Date: 2015-12 Impact factor: 2.493
Authors: David L Steward; Sally E Carty; Rebecca S Sippel; Samantha Peiling Yang; Julie A Sosa; Jennifer A Sipos; James J Figge; Susan Mandel; Bryan R Haugen; Kenneth D Burman; Zubair W Baloch; Ricardo V Lloyd; Raja R Seethala; William E Gooding; Simion I Chiosea; Cristiane Gomes-Lima; Robert L Ferris; Jessica M Folek; Raheela A Khawaja; Priya Kundra; Kwok Seng Loh; Carrie B Marshall; Sarah Mayson; Kelly L McCoy; Min En Nga; Kee Yuan Ngiam; Marina N Nikiforova; Jennifer L Poehls; Matthew D Ringel; Huaitao Yang; Linwah Yip; Yuri E Nikiforov Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Miguel Paja; Carles Zafón; Carmela Iglesias; Aitziber Ugalde; Jose Manuel Cameselle-Teijeiro; Gemma Rodríguez-Carnero; Pilar Fernández-Seara; Emma Anda; Antónia Povoa; Hernán Quiceno; Nancy M Sánchez-Gómez; Clarisa González; Luis García-Pascual; Inés Gómez de la Riva; Concha Blanco; Telma Meizoso; Garcilaso Riesco-Eizaguirre; Ismael Capel; María Victoria Ortega; Isabel Mancha; Montserrat Chao; Victoria Alcázar; Esther Roselló; Javier Maravall; Susana López-Agulló; Antonia Pérez-Lázaro; Pascual Meseguer; Javier Sanz; Jose J Paricio; Saioa Echeverría; Ángel Castaño; Rosa M Bella Journal: Endocrine Date: 2021-01-23 Impact factor: 3.633
Authors: Zubair W Baloch; Sylvia L Asa; Justine A Barletta; Ronald A Ghossein; C Christofer Juhlin; Chan Kwon Jung; Virginia A LiVolsi; Mauro G Papotti; Manuel Sobrinho-Simões; Giovanni Tallini; Ozgur Mete Journal: Endocr Pathol Date: 2022-03-14 Impact factor: 3.943